AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01396213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: gelatin capsule
Study NCT01032720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound will be used to image knee joint and guide needle for intra-articular corticosteroid injection.
Study NCT01032720 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham ultrasound
Description: Knee CS injection will be performed in the same method as the US-guided injection except that the US machine will be turned off. Study patient will be unaware of whether US machine is on or off.
Study NCT00617175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Defibrillator
Description: Number of 30 out of 40 intervals to detect (NID)Fast Ventricular Tachycardia
Study NCT00617175 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Defibrillator
Description: number of 18 out of 24 intervals to detect (NID)Fast Ventricular Tachycardia
Study NCT01810003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High DHA
Description: 10 week supplementation period
Study NCT01810003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High EPA
Description: 10 week supplementation period
Study NCT01810003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 week supplementation period
Study NCT01797263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: A 12-week yoga intervention modified for Veterans with fibromyalgia. Each weekly session will last approximately 75 minutes. The standardized sequence of yoga poses will be introduced to participants and the instructor will tailor them to the participant's needs and abilities. Deep breathing exercises will be taught and emphasized throughout every session. Participants will be encouraged to exercise according to their limits, rather than rigid adherence to posture techniques. The yoga intervention will be tailored to the individual. It will include low intensity, low impact modified poses adapted with pathophysiologic changes of fibromyalgia in mind. Participants will also be given a Playaway(c) device with guided relaxation exercise recorded on it and asked to listen to it three times a week to reinforce the in person yoga session content.
Study NCT01797263 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Structured Exercise
Description: A 12-week group exercise session consisting of a graded aerobic exercise program. The program will start at low intensity with gradual increases in exercise intensity and duration. Each weekly session will last 75 minutes. The fitness instructor will teach participants to use a table-top ergometer at a sub-maximal level, determine baseline fitness, and develop an individualized exercise prescription. The fitness instructor will provide educational tips on exercise and selection of physical activities. Participants will be given a pedometer and heart rate monitor to track their exercise at home. They will also be given an exercise DVD to use at home.
Study NCT03793907 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FitBit
Description: Wear Fitbit
Study NCT03793907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03793907 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03793907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03793907 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03793907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Complete strength training
Study NCT03793907 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STEPS to Enhance Physical Activity
Description: Complete a walking program
Study NCT01539226 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaginal Ring
Description: Dapivirine Vaginal Ring containing 0.0 mg of dapivirine
Study NCT01539226 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Ring, 25 mg
Description: Dapivirine Vaginal Ring containing 25 mg of dapivirine
Study NCT03111420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor
Description: Administration of P2Y12 inhibitor antiplatelet therapy
Study NCT03111420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platelet function test
Description: Blood is drawn for testing of platelet aggregation activity
Study NCT04188262 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NVS Therapy
Description: Combination Product: NVS Therapy which includes NVS Injection (investigational product) and the following investigational devices: NVS Delivery Catheter, NVS light Fiber, and NVS light source.
Study NCT00118209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: IV or CIVI
Study NCT01632891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: Participants received two 200 mg/50 mg tablets of lopinavir/ritonavir orally twice daily.
Study NCT01632891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir disoproxil fumarate
Description: Participants received one 200 mg/300 mg tablet of Emtricitabine/tenofovir disoproxil fumarate orally once daily.
Study NCT01742312 — intervention group
Intervention type: RADIATION
Intervention: DEXA scan
Description: all patients will undertake a full body DEXA scan before and after chemotherapy
Study NCT01742312 — intervention group
Intervention type: PROCEDURE
Intervention: Muscle biopsy
Description: All patients will have a muscle biopsy before and after chemotherapy
Study NCT01742312 — intervention group
Intervention type: OTHER
Intervention: cardio-pulmonary exercise testing (CPEX)
Description: patients will undertake exercise in the form of an exercise bike whilst having their cardiac and ventilatory performance analysed. This will take place before and after neoadjuvant chemotherapy
Study NCT02063568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Study NCT00523939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine liposome injection
Description: 50 mg intrathecal every 14 days for 8 doses, then every 28 days for six doses
Study NCT03194269 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EARFOLD®
Description: EARFOLD® implant is inserted subcutaneously using the sterile disposable EARFOLD® introducer under local anaesthetic
Study NCT00317629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: controlled nitric oxide releasing patch
Description: daily nitric oxide patch application during 20 days
Study NCT00317629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meglumine antimoniate
Description: 20mg/kg daily during 20 days
Study NCT03081832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Infant included in the ancient study (repeated administrations of oxytocin in infants with Prader Willi Syndrome aged from 0 to 6 months)
Study NCT03081832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Not treated.
Study NCT02771977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug-specific alert
Description: A drug-specific alert, informing the provider of the presence of AKI as well as recent exposure to a potentially nephrotoxic agent, will be fired.
Study NCT04492982 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: 1 hour of group format, guided yoga practice
Study NCT04492982 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Distress Tolerance
Description: 1 hour didactic group format, to develop distress tolerance skills
Study NCT01030419 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based, DVD-delivered physical activity
Description: Subjects will be participating in a home-based physical activity program that focuses on flexibility, toning and balance. Exercises will be progressive over the six-months and will highlight modifications for varying levels. This program will be delivered on 3 DVDs. Participants will be asked to exercise with the DVD at least three times per week. Additionally, they will be encouraged to add two days of aerobic activity (e.g. walking) each week.
Study NCT01030419 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care/Wait list
Description: Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD afer the completion of the 12-month follow-up testing.
Study NCT02071225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: 70 milligrams per square meter (mg/m\^2) given by intravenous (IV) infusion on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of subsequent cycles.
Study NCT02071225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obinutuzumab
Description: 1000 mg given by IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of subsequent cycles.
Study NCT03280238 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measurement of pupil dilation and analgesia nociception index
Description: painful electrical stimuli of various intensities were administered to the subjects after which changes in pupil diameter and analgesia nociception index were measured
Study NCT01569295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib 150 mg administered orally twice daily
Study NCT01569295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m\^2 on Day 1, then 500 mg/m\^2 every 28 days administered intravenously for a maximum of 6 infusions
Study NCT01569295 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375 mg/m\^2 on Day 1, then 500 mg/m\^2 every 28 days administered intravenously for a maximum of 6 infusions
Study NCT01569295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine 70 mg/mg\^2/day on 2 consecutive days every 28 days administered intravenously for a maximum of 12 infusions
Study NCT01569295 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bendamustine
Description: Bendamustine 70 mg/mg\^2/day on 2 consecutive days every 28 days administered intravenously for a maximum of 12 infusions
Study NCT01569295 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match idelalisib
Description: Placebo to match idelalisib administered orally twice daily
Study NCT03145415 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal block
Description: 1 cc per kg of 0.2% ropivicaine in the caudal space given before the start of surgery.
Study NCT03145415 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Pudendal block
Description: 0.5 cc per kg of 0.2% ropivicaine. Half of the volume given as a right pudendal block and the remaining volume given on the left pudendal nerve block given prior to the start of surgery
Study NCT01156545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: BIBW 2992 40mg, once a day, oral intake, every day
Study NCT01156545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBW 2992
Description: BIBW 2992 40mg, once a day, oral intake, every day
Study NCT01156545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: simvastatin 40mg, once a day, oral intake, every day.
Study NCT01507311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: A single dose injected subcutaneously (under the skin)
Study NCT01507311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A single dose injected subcutaneously (under the skin)
Study NCT03388151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam 3 mg i.v added to fentanyl 0.5 ug/kg till reaching satisfactory level of sedation
Study NCT03388151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol 1 mg/kg i.v added to fentanyl 0.5 ug/kg i.v till reaching satisfactory level of sedation
Study NCT01387659 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric emptying test
Description: Gastric emptying tests will be performed at baseline, 6 months and 12 months
Study NCT03784638 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lingually-based triangle flap design
Description: A mucoperiosteal lingually-based triangle flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 4-0 silk sutures. The patients will be invited after one week for removing the sutures.
Study NCT03784638 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: buccally based triangular flap design
Description: A mucoperiosteal buccally based triangular flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 4-0 silk sutures. The patients will be invited after one week for removing the sutures.
Study NCT00826969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: 320µg Ciclesonide versus Placebo
Study NCT00826969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02653625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc 150 mg
Description: One tablet of CVC 150 mg once daily taken with food in the morning.
Study NCT01807403 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker.
Study NCT02042352 — intervention group
Intervention type: OTHER
Intervention: pH glove
Study NCT00485264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir poloxamer film coated tablet
Description: Final Selected Dose: 400-mg tablet taken orally twice daily.
Study NCT00485264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir chewable tablet
Description: Final Selected Dose: Weight based dose of \~6 mg/kg according to the dosing table, to a maximum dose of 300 mg, taken orally twice daily.
Study NCT00485264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir oral granules for suspension (20 mg/mL)
Description: Weight based dose of \~6 mg/kg orally every 12 hours according to dosing table in protocol or the dose determined by review of all available data.
Study NCT00485264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir poloxamer film coated tablet
Description: Final Selected Dose: 400-mg tablet taken orally twice daily for participants weighing at least 25 kg. Participants \< 25 kg were switched to a weight-based dose of the chewable tablet.
Study NCT01295749 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laryngeal tube ventilation and continuous chest compression
Description: Comparison of no flow time between two strategies in out of hospital cardiac arrest
Study NCT01295749 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: laryngeal tube ventilation and continuous chest compression
Description: Comparison of no flow time between two strategies in out of hospital cardiac arrest
Study NCT01644656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARFI ultrasound
Description: ARFI imaging of the liver and spleen will be performed immediately before transjugular liver biopsy and HVPG procedures
Study NCT04333160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTA-004
Description: Patients will undergo a single intra-articular injection of JTA-004 into the knee joint
Study NCT04333160 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hylan G-F 20
Description: Patients will undergo a single intra-articular injection of Hylan G-F 20 into the knee joint
Study NCT04333160 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will undergo a single intra-articular injection of placebo into the knee joint
Study NCT03063008 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PEEK
Description: Procedure/Surgery:~TLIF fusion with common PEEK cages.
Study NCT03063008 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TiPEEK
Description: Procedure/Surgery:~TLIF fusion with titanium coated PEEK cages.
Study NCT02046044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Study NCT02046044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Study NCT04999059 — intervention group
Intervention type: OTHER
Intervention: Safety and Efficacy Assessments
Description: Safety evaluations, disease-specific assessments, and other assessments to monitor for long-term complications of gene therapy intervention.
Study NCT02205073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo RD + AVP SD
Description: Placebo (matching to study drug) repeat doses + intranasal AVP single dose
Study NCT02205073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo RD + Placebo SD
Description: Placebo (matching to study drug) repeat doses + intranasal Placebo (matching to intranasal AVP) single dose
Study NCT02205073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG7314 RD + AVP SD
Description: RG7314 repeat doses + intranasal AVP single dose
Study NCT02902523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viread® tablet 300mg
Description: Single dose administration(PO) in the fasted state
Study NCT02902523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUG116 tablet 245mg
Description: Single dose administration(PO) in the fasted state
Study NCT03511027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SME + Karie Device
Description: For the duration of the study, participants will use the Karie device to promote medication adherence. The Karie device prompts users to take their medication in the right amount at the right time.
Study NCT03511027 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SME only
Description: At discharge, participants will be provided with self-medication education.
Study NCT02213159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Study NCT02213159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study NCT03401463 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traning seminar
Description: There will be provided 30 min training seminar on the function of endotracheal cuff and cuff pressure.
Study NCT02045446 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Study NCT02045446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance chemotherapy
Description: Maintenance chemotherapy
Study NCT02045446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy
Description: Maintenance chemotherapy
Study NCT01988181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BVM-UF biofeedback
Description: The Fresenius 5008 uses an ultrasound and temperature monitor incorporated into the machine to detect ultrasonic velocity and temperature changes to derive the total protein concentration, which is a sum of total plasma proteins and hemoglobin. The relative blood volume is calculated at by dividing the initial concentration of total protein by the total protein concentration at any given time, multiplied by 100. The HD software is based on the critical blood volume entered at the beginning of the dialysis session for each individual patient. The UF rate is adjusted based on the changes in the relative blood volume to the patient's critical relative blood volume.
Study NCT01988181 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fresenius 5008 HD machine (Fresenius Medical Care, Bad Homburg, Germany)
Description: For an 8-week period, patients in the best clinical practice (control) phase will use their same prescription as the run-in phase, dialysate sodium of 138mmol/L, dialysate calcium of 1.25mmol/L, dialysate temperature of 36oC, and constant UF rate. BVM will be disabled in this group.
Study NCT01988181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fresenius 5008 HD machine (Fresenius Medical Care, Bad Homburg, Germany)
Description: For an 8-week period, patients in the best clinical practice (control) phase will use their same prescription as the run-in phase, dialysate sodium of 138mmol/L, dialysate calcium of 1.25mmol/L, dialysate temperature of 36oC, and constant UF rate. BVM will be disabled in this group.
Study NCT04143373 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: warm saline irrigation
Description: The objective of this research was to compare the effect of irrigation during impacted mandibular third molar surgery, with normal saline of 25 ± 2 ° C and 37 ± 1 ° C for control and experimental sides, respectively.